Literature DB >> 32339250

A potential ex vivo infection model of human induced pluripotent stem cell-3D organoids beyond coronavirus disease 2019.

Hang Zhou1, Li-Ping Liu1, Mei Fang1, Yu-Mei Li2, Yun-Wen Zheng1,3,4,5,6.   

Abstract

The novel coronavirus disease 2019 (COVID-19) outbreak began in the city of Wuhan, whereupon it rapidly spread throughout China and subsequently across the world. Rapid transmission of COVID-19 has caused wide-spread panic. Many established medications have been used to treat the disease symptoms; however, no specific drugs or vaccines have been developed. Organoids derived from human induced pluripotent stem cells (iPSCs) may serve as suitable infection models for ex vivo mimicking of the viral life cycle and drug screening. Human iPSC-3D organoids, self-organised tissues with multiple cell environments, have a similar structure and function as real human organs; hence, these organoids allow greater viral infection efficiency, mimic the natural host-virus interactions, and are suitable for long-term experimentation. Here, we suggest the use of a functional human iPSC-organoid that could act as a reliable and feasible ex vivo infection model for investigation of the virus. This approach will provide much needed insight into the underlying molecular dynamics of COVID-19 for the development of novel treatment and prevention strategies.

Entities:  

Year:  2020        PMID: 32339250     DOI: 10.14670/HH-18-223

Source DB:  PubMed          Journal:  Histol Histopathol        ISSN: 0213-3911            Impact factor:   2.303


  35 in total

1.  Long-Term Expansion of Functional Mouse and Human Hepatocytes as 3D Organoids.

Authors:  Huili Hu; Helmuth Gehart; Benedetta Artegiani; Carmen LÖpez-Iglesias; Florijn Dekkers; Onur Basak; Johan van Es; Susana M Chuva de Sousa Lopes; Harry Begthel; Jeroen Korving; Maaike van den Born; Chenhui Zou; Corrine Quirk; Luis Chiriboga; Charles M Rice; Stephanie Ma; Anne Rios; Peter J Peters; Ype P de Jong; Hans Clevers
Journal:  Cell       Date:  2018-11-29       Impact factor: 41.582

2.  Vaccines targeting preS1 domain overcome immune tolerance in hepatitis B virus carrier mice.

Authors:  Yingjie Bian; Zheng Zhang; Zhichen Sun; Juanjuan Zhao; Danming Zhu; Yang Wang; Sherry Fu; Jingya Guo; Longchao Liu; Lishan Su; Fu-Sheng Wang; Yang-Xin Fu; Hua Peng
Journal:  Hepatology       Date:  2017-08-26       Impact factor: 17.425

3.  Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis.

Authors:  Mélanie Drolet; Élodie Bénard; Norma Pérez; Marc Brisson
Journal:  Lancet       Date:  2019-06-26       Impact factor: 79.321

4.  TLR7 Agonist Increases Responses of Hepatitis B Virus-Specific T Cells and Natural Killer Cells in Patients With Chronic Hepatitis B Treated With Nucleos(T)Ide Analogues.

Authors:  Carolina Boni; Andrea Vecchi; Marzia Rossi; Diletta Laccabue; Tiziana Giuberti; Arianna Alfieri; Pietro Lampertico; Glenda Grossi; Floriana Facchetti; Maurizia R Brunetto; Barbara Coco; Daniela Cavallone; Alessandra Mangia; Rosanna Santoro; Valeria Piazzolla; Audrey Lau; Anuj Gaggar; G Mani Subramanian; Carlo Ferrari
Journal:  Gastroenterology       Date:  2018-01-31       Impact factor: 22.682

5.  Tropism, replication competence, and innate immune responses of influenza virus: an analysis of human airway organoids and ex-vivo bronchus cultures.

Authors:  Kenrie P Y Hui; Rachel H H Ching; Stan K H Chan; John M Nicholls; Norman Sachs; Hans Clevers; J S Malik Peiris; Michael C W Chan
Journal:  Lancet Respir Med       Date:  2018-07-11       Impact factor: 30.700

6.  Oral Tecovirimat for the Treatment of Smallpox.

Authors:  Douglas W Grosenbach; Kady Honeychurch; Eric A Rose; Jarasvech Chinsangaram; Annie Frimm; Biswajit Maiti; Candace Lovejoy; Ingrid Meara; Paul Long; Dennis E Hruby
Journal:  N Engl J Med       Date:  2018-07-05       Impact factor: 176.079

7.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.

Authors:  Chaolin Huang; Yeming Wang; Xingwang Li; Lili Ren; Jianping Zhao; Yi Hu; Li Zhang; Guohui Fan; Jiuyang Xu; Xiaoying Gu; Zhenshun Cheng; Ting Yu; Jiaan Xia; Yuan Wei; Wenjuan Wu; Xuelei Xie; Wen Yin; Hui Li; Min Liu; Yan Xiao; Hong Gao; Li Guo; Jungang Xie; Guangfa Wang; Rongmeng Jiang; Zhancheng Gao; Qi Jin; Jianwei Wang; Bin Cao
Journal:  Lancet       Date:  2020-01-24       Impact factor: 79.321

8.  A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster.

Authors:  Jasper Fuk-Woo Chan; Shuofeng Yuan; Kin-Hang Kok; Kelvin Kai-Wang To; Hin Chu; Jin Yang; Fanfan Xing; Jieling Liu; Cyril Chik-Yan Yip; Rosana Wing-Shan Poon; Hoi-Wah Tsoi; Simon Kam-Fai Lo; Kwok-Hung Chan; Vincent Kwok-Man Poon; Wan-Mui Chan; Jonathan Daniel Ip; Jian-Piao Cai; Vincent Chi-Chung Cheng; Honglin Chen; Christopher Kim-Ming Hui; Kwok-Yung Yuen
Journal:  Lancet       Date:  2020-01-24       Impact factor: 79.321

9.  Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study.

Authors:  Nanshan Chen; Min Zhou; Xuan Dong; Jieming Qu; Fengyun Gong; Yang Han; Yang Qiu; Jingli Wang; Ying Liu; Yuan Wei; Jia'an Xia; Ting Yu; Xinxin Zhang; Li Zhang
Journal:  Lancet       Date:  2020-01-30       Impact factor: 79.321

10.  A three-dimensional model of human lung development and disease from pluripotent stem cells.

Authors:  Ya-Wen Chen; Sarah Xuelian Huang; Ana Luisa Rodrigues Toste de Carvalho; Siu-Hong Ho; Mohammad Naimul Islam; Stefano Volpi; Luigi D Notarangelo; Michael Ciancanelli; Jean-Laurent Casanova; Jahar Bhattacharya; Alice F Liang; Laura M Palermo; Matteo Porotto; Anne Moscona; Hans-Willem Snoeck
Journal:  Nat Cell Biol       Date:  2017-04-24       Impact factor: 28.824

View more
  1 in total

Review 1.  SARS-CoV-2: Pathogenesis, Molecular Targets and Experimental Models.

Authors:  G Kanimozhi; B Pradhapsingh; Charan Singh Pawar; Haseeb A Khan; Salman H Alrokayan; N Rajendra Prasad
Journal:  Front Pharmacol       Date:  2021-04-22       Impact factor: 5.810

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.